Analysis of the clinical results of the PMCF study on the REAC ACT, CO and MO-IBZ protocols. Significant reduction of pain and improvement of well-being in patients with CLGI.

Introduction: The clinical challenge of low-grade chronic inflammation

Chronic low-grade inflammation (CLGI) is a silent but pervasive biological substrate underlying persistent symptoms such as chronic pain, sleep disturbances and persistent fatigue. Unlike acute forms, CLGI often evolves in the absence of altered classical biomarkers, making clinical management particularly complex. Technology Radio Electric Asymmetric Conveyer (REAC) This is part of a non-invasive biomodulation approach designed to interact with endogenous bioelectric activity and support adaptive regulatory processes.

Source Analysis: Real-World Prospective Observational Study

The study published in the Journal of Clinical Medicine (2026) evaluated the clinical performance and tolerability of REAC INSIDE BLUE ZONE protocols ACT (Anti-inflammatory Cellular Treatment), CO (Circulatory Optimization) and MO (Metabolic Optimization) in a Post-Market Clinical Follow-Up (PMCF) setting.

Technical Parameters and Methodology

• Sample: 50 adult subjects (age 32-76 years) with CLGI-related symptoms.

• Sequential protocols: Application of ACT (inflammatory modulation), CO (optimization of microcirculation and tissue perfusion) and MO (cellular and systemic metabolic balance).

• Primary endpoint: Change in pain intensity measured by Visual Analog Scale (VAS) at the end of treatment (T1) and at follow-up at 4-8 weeks (T2).

Highlighted results

Statistical analysis showed a significant reduction in pain and an improvement in secondary symptomatic domains:

1. Reduction of Pain: The mean VAS score increased from 6.77 ± 0.94 (baseline) to 4.2 ± 1.0 at the end of treatment (t(49)=21.37, p<0.001, Cohen’s d=3.02).
2. Response rate: The 78% of the participants were classified as “responders”, resulting in a reduction in SEA ≥ 30%.
3. Durability: Clinical benefits were maintained at follow-up (T2), with an average VAS of 4.4 ±1.2.
4. Safety: No adverse events were reported during the study, confirming the high safety profile of the device BENE mod. 110.

Clinical Implications: From Suppression of Symptoms to Restoration of Homeostasis

The observed efficacy should not be interpreted as a mere symptomatic analgesic effect, but as the clinical expression of modulation of adaptive regulatory mechanisms..

• ACT: It intervenes on the subclinical inflammatory response.
• CO: It supports the supply of oxygen and nutrients by optimising microcirculatory dynamics.
• MO: It contributes to the restoration of the metabolic functional balance.

This sequential model reflects an integrative approach aimed at rebalancing fundamental regulatory processes rather than suppressing the symptom in isolation. The data confirms that the protocol is well tolerated It produces progressively visible results, significantly improving the quality of life perceived by patients.

Conclusions

The results of this PMCF study support the clinical performance of the REAC ACT, CO, and MO protocols in the treatment of conditions associated with low-grade chronic inflammation. The durability of the effects and the absence of side effects make this technology an innovative tool for regenerative and restorative medicine.